ECONOMIC MODELING OF MEROPENEM AND CEFEPIME DOSE DE-ESCALATION BASED ON GRAM NEGATIVE SUSCEPTIBILITY

被引：0
|
作者：
Schulz, Lucas [1 ]
Rose, Warren [2 ]
Fish, Jeffrey [1 ]
机构：
[1] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
来源：
CRITICAL CARE MEDICINE | 2009年 / 37卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
847
引用
收藏
页码：A414 / A414
页数：1
相关论文
共 50 条
  • [41] Caution Before Antibiotic De-escalation Following Negative MRSA Nares Testing
    Gaillardetz, Andrew
    AMERICAN FAMILY PHYSICIAN, 2022, 106 (04) : 362 - 363
  • [42] PRACTICE PATTERNS FOR ANTIBIOTIC DE-ESCALATION IN MRSA CULTURE-NEGATIVE SEPSIS
    Sadaka, Farid
    Korobey, Matthew
    Dumm, Alexis
    Wegener, Greggory
    Kumar, Rachna
    Bryant, Alex
    O'Brien, Jackyln
    CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [43] In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin
    Farfour, Eric
    d'Epenoux, Louise Ruffier
    Muggeo, Anaelle
    Alauzet, Corentine
    Cremet, Lise
    Moussalih, Sophie
    Roux, Antoine
    de Verdiere, Sylvie C.
    Bosphore, Amelie
    Corvec, Stephane
    Guillard, Thomas
    Vasse, Marc
    FUTURE MICROBIOLOGY, 2022, 18 (02) : 117 - 126
  • [44] Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer
    White, Richard
    Abel, Stephen
    Hasan, Shaakir
    Verma, Vivek
    Greenberg, Larisa
    Colonias, Athanasios
    Wegner, Rodney E.
    LARYNGOSCOPE, 2020, 130 (04): : E171 - E176
  • [45] Dose De-escalation to the Elective Lymph Nodes in Head and Neck Cancer Reply
    Maguire, Patrick D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (03): : 747 - 747
  • [46] Maximum Tolerated Dose Estimation with Dose De-Escalation Design in a Phase I Clinical Trials
    Jang, Eunah
    Kim, Dongjae
    KOREAN JOURNAL OF APPLIED STATISTICS, 2014, 27 (07) : 1115 - 1123
  • [47] Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA
    den Broeder, Alfons A.
    van der Maas, Aatke
    van den Bemt, Bart J. F.
    RHEUMATOLOGY, 2010, 49 (10) : 1801 - 1803
  • [48] Project PANDA: An Individual and Systems Based Approach to De-Escalation
    Ahmed, O.
    Dhillon, S.
    Restivo, A.
    Singh, M.
    ANNALS OF EMERGENCY MEDICINE, 2022, 80 (04) : S105 - S105
  • [49] Meropenem utilization before and after the implementation of a Best Practice Advisory de-escalation reminder at 72 hours of use
    Stemple, Kristina
    Keller, Lisa
    PHARMACOTHERAPY, 2015, 35 (11): : E303 - E303
  • [50] Negative prognostic impact of dose de-escalation in the "low-risk" volume in primary chemoradiotherapy of nasopharyngeal carcinoma: the Mainz experience
    Mayer, A.
    Grad, C.
    Bostel, T.
    Schmidberger, H.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S76 - S76
12345